

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10502080
Filing Date	2004-10-08
First Named Inventor	BOWEN, J. Phillip
Art Unit	1612
Examiner Name	Brian GULLEDGE
Attorney Docket Number	B40-002

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10502080
Filing Date	2004-10-08
First Named Inventor	BOWEN, J. Phillip
Art Unit	1612
Examiner Name	Brian GULLEDGE
Attorney Docket Number	B40-002

/PEZ/	1	JOHNSON JI et al., Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer 2001, 84(10):1424-1431.	<input type="checkbox"/>
	2	LIU B et al., Pro-angiogenic effect of IFNgamma is dependent on the PI3K/mTOR/translational pathway in human retinal pigmented epithelial cells. Mol. Vis. 2010, 16:184-193.	<input type="checkbox"/>
	3	PHUNG TL et al., Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. Cancer Res. 2007, 67(11):5070-5075. Erratum in: Cancer Res. 2007, 67(13):6528.	<input type="checkbox"/>
	4	SUGGITT M et al., Fifty years of preclinical anticancer drug screening: empirical to target-driven approaches. Clinical Cancer Research 2005, 11:971-981.	<input type="checkbox"/>
	5	TARNAWSKI AS et al., PTEN silencing reverses aging-related impairment of angiogenesis in microvascular endothelial cells. Biochem Biophys Res Commun 2010, 394(2):291-296.	<input type="checkbox"/>
	6	VOSKOGLOU-NOMIKOS T et al., Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical Cancer Research 2003, 9:4227-4239.	<input type="checkbox"/>
	7	WANG D et al., Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 1999, 59(7):1464-1472.	<input type="checkbox"/>
	8	ZHONG H et al., Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60(6):1541-1545.	<input type="checkbox"/>
↓	9		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Paul Zarek/	Date Considered	06/28/2011
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****(Not for submission under 37 CFR 1.99)**

Application Number	10502080
Filing Date	2004-10-08
First Named Inventor	BOWEN, J. Phillip
Art Unit	1612
Examiner Name	Brian GULLEDGE
Attorney Docket Number	B40-002

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.